Cidara posts data from head-to-head trial against Merck antifungal

A phase 2 trial of Cidara Therapeutics’ antifungal prospect rezafungin has met its objectives. The trial found the drug performed numerically better than Merck’s Cancidas, offering Cidara encouragement as it heads toward phase 3 data.